Human study PLS-00062

Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.primary · Biologics : targets & therapy · 2025-03-13 · PMID 40104672 · DOI

Design and participants

Design
Cross-sectional study
Population
Patients diagnosed with aortic valve disease and scheduled for aortic valve replacement (17), and healthy controls (22).
Conditions
Aortic valve disease
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Plasma PGC1α and MOTS-c were lower in aortic valve disease patients than in controls. The authors propose both as potential plasma biomarkers for detecting aortic valve disease, pending studies that include early-stage patients.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: MOTS-c was measured as an endogenous biomarker and was never administered, so the study gives no information on the effects of MOTS-c treatment.
    • small or imprecise: Only 17 patients and 22 healthy controls were recruited, per the abstract.
    • abstract only: Only the abstract is available in the record. No numeric results or methodological details are given.
    • confounding: Cross-sectional comparison with healthy controls; the abstract does not describe how comorbidities or medications were handled.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 40104672, abstract (Conclusion, sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 40104672, abstract (Purpose, sentence 5) · extracted by AI (automated, not verified by a person) · abstract only
    • outcomes: PMID 40104672, abstract (Patients and methods, sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 40104672, abstract (Patients and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 40104672, abstract (Patients and methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).